Publications by authors named "S Iwata"
Objective: To elucidate the association between the changes in intracellular metabolism in the early stage of B cell activation and systemic lupus erythematosus (SLE) pathogenesis.
Methods: CD19 or CD19CD27 (naïve) cells from the peripheral blood of healthy controls and lupus patients were cultured under different stimuli. The changes in intracellular metabolism and signalling pathways in these cells were evaluated.
Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis preceded by bronchial asthma or allergic sinusitis and accompanied by peripheral blood eosinophilia. Immunosuppressive drugs, such as cyclophosphamide in addition to high-dose glucocorticoids, are recommended for induction of remission in patients with severe EGPA. Although mepolizumab is widely recognized as remission induction therapy in non-fatal/non-organ disabling or relapsed/refractory EGPA, its efficacy and safety in induction of remission for severe cases have been ambiguous.
View Article and Find Full Text PDFArticle Synopsis
- * The study created Drp1-deficient mice (aP2-Drp1f/f) to explore the impact of the dynamin-related protein 1 (Drp1) on BAT development and thermogenesis, revealing severe developmental issues and a high mortality rate shortly after birth.
- * Analysis indicated that Drp1 deficiency led to impaired thermogenic and lipogenic gene expression in BAT, disrupted mitochondrial structure, and dysfunctional thermogenesis in surviving adult mice, highlighting Drp1's critical role in both BAT function and neonatal
Chondrosarcoma (CS) is a malignant tumor that produces cartilaginous matrix and is the second most common primary bone sarcoma. CS encompasses a range of histological subtypes, with high-grade conventional central CS being particularly rare, occurring at a rate of 1.81 cases per 1 million person-years.
View Article and Find Full Text PDFBackground: This study aimed to assess the 1-year clinical outcomes and predictors of technical success in acute limb ischemia (ALI) treatment.
Methods: A sub-analysis of the REtroSpective multiCenter study of endovascUlar or surgical intErvention for ALI (RESCUE ALI) study involved 185 patients with ALI and technical success (n = 131) or failure (n = 54) treated via surgical, endovascular, or hybrid revascularization between January 2015 and August 2021. The primary endpoint was 1-year amputation-free survival (AFS), and the secondary endpoints included preoperative complications and 1-year reintervention.